Status:
COMPLETED
Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Glioblastoma
Glioma
Eligibility:
All Genders
Brief Summary
The purpose of this surveillance is to evaluate the postmarketing safety and efficacy of Temodal capsule (temozolomide) under actual conditions of use, and to understand some of the following points t...
Eligibility Criteria
Inclusion
- Participants who are prescribed with temozolomide by local labeling:
- participants with newly diagnosed glioblastoma multiforme;
- participants with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
Exclusion
- N/A
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
682 Patients enrolled
Trial Details
Trial ID
NCT00723827
Start Date
March 1 2008
End Date
September 1 2011
Last Update
January 30 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.